Business Context and Reporting Period
Company: iBio, Inc. (Nasdaq: IBIO)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended June 30, 2026
Business Overview: iBio is a clinical-stage biotechnology company leveraging an AI Drug Discovery Platform to develop precision antibodies for obesity, cardiometabolic, and cardiopulmonary diseases. The company recently transitioned to a clinical-stage entity by initiating a Phase 1 trial for its lead candidate, IBIO-600, in Australia in June 2026. The company operates as a single reportable segment and is classified as a smaller reporting company.
Key Financial Metrics
| Metric (in thousands) | Fiscal 2026 | Fiscal 2025 |
|---|---|---|
| Revenue | $100 | $400 |
| Net Loss | $(33,044) | $(18,377) |
| Loss Per Share (Basic & Diluted) | $(0.32) | $(1.75) |
| Research & Development Expenses | $19,643 | $8,312 |
| General & Administrative Expenses | $10,595 | $10,690 |
| Impairment of Intangible Assets | $5,003 | $0 |
| Cash and Cash Equivalents (End of Period) | $56,395 | $8,582 |
| Investments in Debt Securities | $31,644 | $0 |
| Total Current Assets | $92,221 | $9,721 |
| Total Liabilities | $13,397 | $8,305 |
| Accumulated Deficit | $(365,268) | $(332,224) |
Liquidity: As of June 30, 2026, the company held approximately $88 million in cash, cash equivalents, and investments in debt securities. Management believes this is sufficient to fund operations for at least 12 months from the filing date.
Material Changes vs. Prior Period
- Revenue: Decreased to $0.1 million from $0.4 million, reflecting minimal revenue from collaborative services.
- Net Loss: Increased to $33.0 million from $18.4 million. The increase was driven by higher R&D spending and a $5.0 million impairment charge.
- R&D Expenses: Increased 136% to $19.6 million. This was primarily due to $8.4 million in increased spending on consultants and outside services (including NHP studies and CMC activities) for IBIO-600 and IBIO-610, plus a $2.5 million development milestone payment.
- Impairment Charges: Recorded a $5.0 million impairment of the IBIO-101 indefinite-lived intangible asset (oncology program) following a strategic pivot away from immuno-oncology to focus on cardiometabolic diseases.
- Capital Position: Significant improvement in liquidity due to an August 2025 underwritten public offering (approx. $46.5 million net proceeds), a January 2026 private placement (approx. $26 million gross proceeds), and warrant exercises totaling approx. $33.4 million during the fiscal year.
Guidance, Outlook, and Risks
Management Commentary and Pipeline Progress
- IBIO-600 (Myostatin Antibody): Dosed first participant in Phase 1 SAD trial in Australia in June 2026. 31 participants enrolled across four cohorts. Preparing to advance to Multiple Ascending Dose (MAD) portion.
- IBIO-610 (Activin E Antibody): Advanced to IND-enabling studies. Preclinical data in non-human primates showed a terminal half-life of ~33 days (projected human half-life up to 100 days) and fat-selective weight loss. First-in-human trials anticipated in H1 2027.
- IBIO-800 (Bispecific Antibody): Development candidate nominated in June 2026 for potential use in obesity and PH-HFpEF. CMC and nonclinical testing initiated.
- Strategic Pivot: Ceased marketing of oncology assets (IBIO-101) and fully impaired the asset to focus resources on obesity and cardiometabolic programs.
Risks and Contingencies
- Going Concern: While liquidity has improved, the company has a history of significant losses and negative cash flows. Continued ability to operate depends on raising additional capital.
- Regulatory Acceptance: The Phase 1 trial for IBIO-600 is being conducted in Australia. There is a risk that the FDA may not accept data from this foreign trial without additional U.S. studies.
- Intellectual Property: Key assets (IBIO-600, IBIO-610) rely on licenses from AstralBio. Termination of these licenses could halt development.
- Stock Price Volatility: The company previously received a Nasdaq non-compliance notice regarding minimum bid price (though compliance was regained in November 2025). Continued listing depends on maintaining compliance.
Investor Verification Checklist
- Cash Runway: Verify the $88 million cash position against the projected burn rate to confirm the 12-month liquidity assertion.
- IBIO-600 Trial Data: Monitor the safety and pharmacokinetic data release from the Australian Phase 1 trial to assess FDA acceptance likelihood.
- Capital Requirements: Review the terms of the ATM agreement with Jefferies and the status of the $100 million potential sale capacity.
- License Obligations: Confirm the status of milestone payments and equity issuance caps under the AstralBio license agreements (up to $28 million per asset).
- Impairment Finality: Ensure the $5.0 million impairment of the oncology asset is fully recognized and no further write-downs are anticipated for that segment.